These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 21222549)

  • 21. Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's disease.
    León R; Garcia AG; Marco-Contelles J
    Med Res Rev; 2013 Jan; 33(1):139-89. PubMed ID: 21793014
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Concepts for the treatment of Alzheimer's disease: molecular mechanisms and clinical application.
    Pietrzik C; Behl C
    Int J Exp Pathol; 2005 Jun; 86(3):173-85. PubMed ID: 15910551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting amyloid precursor protein secretases: Alzheimer's disease and beyond.
    Ganjei JK
    Drug News Perspect; 2010 Nov; 23(9):573-84. PubMed ID: 21152452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody-based therapy in Alzheimer's disease.
    Pul R; Dodel R; Stangel M
    Expert Opin Biol Ther; 2011 Mar; 11(3):343-57. PubMed ID: 21261567
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early investigational drugs targeting tau protein for the treatment of Alzheimer's disease.
    Anand K; Sabbagh M
    Expert Opin Investig Drugs; 2015; 24(10):1355-60. PubMed ID: 26289787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drugs targeting Alzheimer's disease: some things old and some things new.
    Michaelis ML
    J Pharmacol Exp Ther; 2003 Mar; 304(3):897-904. PubMed ID: 12604663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Secretases as therapeutic targets for Alzheimer's disease.
    Woo HN; Baik SH; Park JS; Gwon AR; Yang S; Yun YK; Jo DG
    Biochem Biophys Res Commun; 2011 Jan; 404(1):10-5. PubMed ID: 21130746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. beta-Amyloid as a molecular therapeutic target in Alzheimer's disease.
    Adlard PA; James SA; Bush AI; Masters CL
    Drugs Today (Barc); 2009 Apr; 45(4):293-304. PubMed ID: 19499094
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protective effect of the phosphodiesterase III inhibitor cilostazol on amyloid β-induced cognitive deficits associated with decreased amyloid β accumulation.
    Park SH; Kim JH; Bae SS; Hong KW; Lee DS; Leem JY; Choi BT; Shin HK
    Biochem Biophys Res Commun; 2011 May; 408(4):602-8. PubMed ID: 21530492
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Small-molecule BACE1 inhibitors: a patent literature review (2006 - 2011).
    Probst G; Xu YZ
    Expert Opin Ther Pat; 2012 May; 22(5):511-40. PubMed ID: 22512789
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disease-modifying therapies in Alzheimer's disease.
    Salloway S; Mintzer J; Weiner MF; Cummings JL
    Alzheimers Dement; 2008 Mar; 4(2):65-79. PubMed ID: 18631951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progress in Alzheimer's disease drug discovery: an update.
    Williams M
    Curr Opin Investig Drugs; 2009 Jan; 10(1):23-34. PubMed ID: 19127484
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The development of new therapeutics for Alzheimer's disease.
    Carter MD; Simms GA; Weaver DF
    Clin Pharmacol Ther; 2010 Oct; 88(4):475-86. PubMed ID: 20811351
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discontinued disease-modifying therapies for Alzheimer's disease: status and future perspectives.
    Imbimbo BP; Lozupone M; Watling M; Panza F
    Expert Opin Investig Drugs; 2020 Sep; 29(9):919-933. PubMed ID: 32657175
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changing perspectives on Alzheimer's disease: thinking outside the amyloid box.
    D'Alton S; George DR
    J Alzheimers Dis; 2011; 25(4):571-81. PubMed ID: 21460435
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease.
    D'Onofrio G; Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Paroni G; Cascavilla L; Seripa D; Pilotto A
    Expert Opin Drug Discov; 2012 Jan; 7(1):19-37. PubMed ID: 22468891
    [TBL] [Abstract][Full Text] [Related]  

  • 37. α7 Nicotinic receptor modulators for cognitive deficits in schizophrenia and Alzheimer's disease.
    Geerts H
    Expert Opin Investig Drugs; 2012 Jan; 21(1):59-65. PubMed ID: 22047592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Creativity and dementia: emerging diagnostic and treatment methods for Alzheimer's disease.
    Cummings JL; Miller BL; Christensen DD; Cherry D
    CNS Spectr; 2008 Feb; 13(2 Suppl 2):1-20; quiz 22. PubMed ID: 18264030
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pharmacotherapy for the treatment of Alzheimer's disease--the present state and the development in the future].
    Yamaguchi N; Okada N; Sugiyama T
    Nihon Rinsho; 2002 Jan; 60(1):107-11. PubMed ID: 11808319
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alzheimer's disease: a general introduction and pathomechanism.
    Finder VH
    J Alzheimers Dis; 2010; 22 Suppl 3():5-19. PubMed ID: 20858960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.